Evidence map›Paper›PMID 38130501›Full record

ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2023

Utilization of a High Potency Probiotic Product for Prevention of Necrotizing Enterocolitis in Preterm Infants at a Level IV NICU.

Annie Bui, Emory Johnson, Michael Epshteyn, Caitlin Schumann, Clair Schwendeman

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Annie BuiDepartment of Pharmacy (AB, EJ, ME), Medical City Dallas Hospital, Dallas, TX.
Emory JohnsonDepartment of Pharmacy (AB, EJ, ME), Medical City Dallas Hospital, Dallas, TX.
Michael EpshteynDepartment of Pharmacy (AB, EJ, ME), Medical City Dallas Hospital, Dallas, TX.
Caitlin SchumannDepartment of Nursing (C. Schumann), Medical City Dallas Hospital, Dallas, TX.
Clair SchwendemanDepartment of Neonatology (C. Schwendeman), Pediatrix Medical Group, North Dallas Practice, Dallas, TX.
Medical City Dallas Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Necrotizing enterocolitis (NEC) is a serious gastrointestinal disease that can be seen in premature infants with high risk for morbidity and mortality. There is currently no US Food and Drug Administration (FDA) medication approved for the prevention of NEC. Despite great heterogeneity among available studies, large meta-analyses of clinical trials have demonstrated the efficacy of multiple-strain probiotics in reducing NEC and all-cause mortality. In 2020, Medical City Dallas's Level IV neonatal intensive care unit (NICU) implemented a probiotic protocol for NEC prevention. As a result, a reduction in NEC was observed, with no occurrence of probiotic-related sepsis.

Indexed as

BifidobacteriumLactobacillusnecrotizing enterocolitispremature infantprobioticStreptococcus thermophilusVisbiome

Identifiers

PMID38130501
PMCPMC10731933
OpenAlexW4387312837

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.